-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
VBI Vaccines (NASDAQ:VBIV) Stock Crosses Below 200-Day Moving Average of $1.13
VBI Vaccines (NASDAQ:VBIV) Stock Crosses Below 200-Day Moving Average of $1.13
VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.13 and traded as low as $0.85. VBI Vaccines shares last traded at $0.87, with a volume of 810,237 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Raymond James decreased their price target on VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
Get VBI Vaccines alerts:VBI Vaccines Stock Down 1.6 %
The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.13. The company has a market cap of $224.55 million, a P/E ratio of -2.23 and a beta of 1.86. The company has a current ratio of 2.29, a quick ratio of 2.19 and a debt-to-equity ratio of 0.20.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.11). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.70 million. VBI Vaccines had a negative net margin of 15,391.36% and a negative return on equity of 75.37%. On average, equities analysts anticipate that VBI Vaccines Inc. will post -0.37 EPS for the current year.Hedge Funds Weigh In On VBI Vaccines
A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. State Street Corp grew its position in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after buying an additional 3,844,698 shares in the last quarter. Millennium Management LLC grew its position in shares of VBI Vaccines by 211.7% during the 2nd quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after buying an additional 1,209,393 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of VBI Vaccines by 358.7% during the 2nd quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock worth $638,000 after buying an additional 617,400 shares in the last quarter. Frontier Wealth Management LLC grew its position in shares of VBI Vaccines by 1,571.7% during the 1st quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock worth $951,000 after buying an additional 565,800 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock worth $1,343,000 after buying an additional 380,839 shares in the last quarter. Institutional investors own 39.96% of the company's stock.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Recommended Stories
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.13 and traded as low as $0.85. VBI Vaccines shares last traded at $0.87, with a volume of 810,237 shares changing hands.
VBI Vaccines Inc.(纳斯达克代码：VBIV-GET Rating)的股价在周五的交易中跌破200日移动均线，200日移动均线切入位为1.13美元，最低交易价格为0.85美元。VBI Vaccines的股票最新报0.87美元，成交量为810,237股。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, Raymond James decreased their price target on VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
另外，雷蒙德·詹姆斯将VBI疫苗的目标价从6.00美元下调至5.00美元，并在8月9日(星期二)的一份报告中对该股设定了“强势买入”评级。
VBI Vaccines Stock Down 1.6 %
VBI疫苗股价下跌1.6%
The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.13. The company has a market cap of $224.55 million, a P/E ratio of -2.23 and a beta of 1.86. The company has a current ratio of 2.29, a quick ratio of 2.19 and a debt-to-equity ratio of 0.20.
该公司的50日简单移动均线切入位在0.94美元，200日简单移动均线切入位在1.13美元。该公司市值为2.2455亿美元，市盈率为-2.23，贝塔系数为1.86。该公司的流动比率为2.29，速动比率为2.19，债务权益比率为0.20。
Hedge Funds Weigh In On VBI Vaccines
对冲基金参与VBI疫苗
A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. State Street Corp grew its position in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after buying an additional 3,844,698 shares in the last quarter. Millennium Management LLC grew its position in shares of VBI Vaccines by 211.7% during the 2nd quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after buying an additional 1,209,393 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of VBI Vaccines by 358.7% during the 2nd quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock worth $638,000 after buying an additional 617,400 shares in the last quarter. Frontier Wealth Management LLC grew its position in shares of VBI Vaccines by 1,571.7% during the 1st quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock worth $951,000 after buying an additional 565,800 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock worth $1,343,000 after buying an additional 380,839 shares in the last quarter. Institutional investors own 39.96% of the company's stock.
一些对冲基金和其他机构投资者最近改变了他们在VBIV的头寸。道富集团在第一季度持有的VBI疫苗股票增加了31.1%。道富集团目前持有这家生物制药公司16,216,811股股票，价值26,920,000美元，上一季度又购买了3,844,698股。千禧管理有限责任公司在第二季度增持了211.7%的VBI疫苗股份。Millennium Management LLC现在拥有这家生物制药公司1,780,752股股票，价值1，44万美元，上个季度又购买了1,209,393股。复兴科技有限公司在第二季度将其在VBI疫苗公司的股票头寸增加了358.7%。复兴科技有限责任公司现在持有这家生物制药公司78.95万股股票，价值63.8万美元，上个季度又购买了61.74万股。FronTier Wealth Management LLC在第一季度将其在VBI疫苗股份的头寸增加了1,571.7%。FronTier Wealth Management LLC现在拥有601,800股这家生物制药公司的股票，价值951,000美元，上个季度又购买了565,800股。最后，美国银行DE在第一季度将其在VBI疫苗公司的股票头寸增加了88.9%。美国银行DE现在持有809,425股这家生物制药公司的股票，价值1,343,000美元，此前在上个季度又购买了380,839股。机构投资者持有该公司39.96%的股份。
About VBI Vaccines
关于VBI疫苗
(Get Rating)
(获取评级)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI疫苗公司是一家生物制药公司，开发和销售用于治疗传染病和免疫肿瘤学的疫苗。该公司提供一种预防性乙肝疫苗Sci-B-Vac。它还参与VBI-2601(BRII-179)的开发，VBI-2601(BRII-179)是治疗慢性乙肝感染的免疫治疗候选药物。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于VBI疫苗的研究报告(VBIV)
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到VBI疫苗的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对VBI疫苗和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧